TScan Therapeutics (TCRX) EBT (2020 - 2026)

TScan Therapeutics (TCRX) has reported EBT for 7 consecutive years, with -$30.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 17.84% year-over-year to -$30.4 million in Q2 2026; TTM through Jun 2026 was -$117.7 million, a 13.25% increase from a year earlier, with the FY2025 full-year figure at -$129.8 million, down 2.66% from the prior year.
• EBT was -$30.4 million for Q2 2026 at TScan Therapeutics, down from -$28.7 million in the prior quarter.
• Over five years, EBT peaked at -$15.1 million in Q2 2022 and troughed at -$37.0 million in Q2 2025.
• A 5-year average of -$26.1 million and a median of -$26.4 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT plunged 104.2% in 2022 and jumped 33.82% in 2025, its largest moves.
• Over 5 years, EBT stood at -$18.7 million in 2022, then fell by 4.75% to -$19.6 million in 2023, then tumbled by 77.02% to -$34.7 million in 2024, then jumped by 33.82% to -$23.0 million in 2025, then tumbled by 32.13% to -$30.4 million in 2026.
• The last three EBT figures came in at -$30.4 million (Q2 2026), -$28.7 million (Q1 2026), and -$23.0 million (Q4 2025), per Business Quant data.